Tipsheet
What matters at India’s listed companies
Earnings · Pharmaceuticals · Micro cap

Phaarmasia's ₹17.57 cr profit is a one-off land sale

The nano-cap swung to profit on a ₹18.99 cr asset disposal, while operational revenue nearly doubled to ₹47.21 cr.

2 earlier stories on Phaarmasia Ltd.
Mkt cap₹68.47 cr
P/E3.90×
ROE0.00%
Debt / eq.0.00
₹18.99 cr One-time gain from selling land and buildings, 107% of FY26 net profit.

What's new

  • Phaarmasia swung to a net profit of ₹17.57 cr from a loss of ₹1.59 cr a year earlier.
  • The turnaround was driven by a one-off ₹18.99 cr gain from selling land and buildings.
  • Operational revenue nearly doubled to ₹47.21 cr; the company ended the year with zero debt and ₹10.99 cr cash.

Why this matters

Strip out the asset sale, and Phaarmasia is a tiny pharma company with ₹47 cr in revenue and a market cap of ₹53 cr. The land sale generated a gain equal to 36% of its entire market capitalisation, dwarfing its operational performance. That's where the profit came from.

What we're watching

  • Whether operational revenue growth can sustain its near-doubling pace without asset sales.
  • How the company deploys its new ₹10.99 cr cash pile.
  • The next quarterly results to gauge the core business trajectory.

The full read

Phaarmasia's headline numbers look strong. A ₹17.57 cr profit versus a ₹1.59 cr loss. Revenue nearly doubled to ₹47.21 cr. Cash jumped from ₹0.36 cr to ₹10.99 cr. The catch is the source of the profit. The company sold land and buildings for a one-off gain of ₹18.99 cr. That single transaction was 107% of the reported net profit. For a ₹53 cr nano-cap, the gain alone was equivalent to 36% of its market capitalisation. The core pharma business, while growing revenue, did not generate the profit on its own. The balance sheet is now debt-free with a meaningful cash pile, but that's a function of the asset sale, not operational cash flow. The filing says nothing about repeatable earnings power.

Questions answered

How much of the ₹17.57 cr profit came from the land sale?
The ₹18.99 cr exceptional gain from selling land and buildings exceeded the total net profit, meaning the core business was either break-even or slightly loss-making before the one-off.
Is the operational revenue growth sustainable?
The filing shows revenue nearly doubled to ₹47.21 cr but provides no details on the drivers or guidance. The company is a nano-cap with a ₹53 cr market cap, making the base volatile.
What does the balance sheet look like after the sale?
Phaarmasia ended the year with zero debt and a cash balance of ₹10.99 cr, up from just ₹0.36 cr a year prior, a direct result of the asset disposal proceeds.
Why is this result unusual for a company of this size?
The land-sale gain was equal to 36% of the company's entire market capitalisation. For a ₹53 cr nano-cap, a one-off of this magnitude distorts the headline profit and is not repeatable.
Mentioned: Phaarmasia Ltd · ₹18.99 cr land sale · ₹53 cr market cap
Primary source BSE · NSE · Tijori

An independent reading of the company's own disclosure — the primary filing above is the final word.

Company snapshot

Phaarmasia Ltd.

Pharmaceuticals
₹66 cr
P/E 3.73×

Latest quarter · Mar 2026

Sales₹8 cr
Net profit−₹1 cr
Op. margin−8.6%
EPS−₹1.03

Strength & growth

Debt / equity0.00×
Current ratio0.65×
Sales CAGR+13.2%
EPS CAGR+81.5%
  1. 29 May 2026 · 7:37 PM IST Phaarmasia's ₹17.57 cr profit is a one-off land sale
  2. 46d ago Phaarmasia's ₹18.99 cr land sale flips a ₹1.59 cr loss into a ₹17.57 cr profit
  3. 46d ago Phaarmasia approves FY26 results. The filing omits the numbers.